We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Requests New Trial for Aldeyra Therapeutics’ Dry Eye Disease Drug
FDA Requests New Trial for Aldeyra Therapeutics’ Dry Eye Disease Drug
Aldeyra Therapeutics on Monday announced receipt of an FDA complete response letter (CRL) for the NDA of reproxalap, for the treatment of dry eye disease, asking the company to conduct an additional trial to show the efficacy of the drug.
